HealthQuill Alexion Pharmaceuticals
AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys, failed to meet its main goal of helping people to live longer.
Drugs Health Pharma

AstraZeneca’s trial drug for AL amyloidosis fails to meet survival goal

HQ Team July 16, 2025: AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys,.

Read More
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug Administration.
Drugs Health Pharma

US drug regulator clears Amgen’s biosimilar to treat rare blood disorder

The US drug regulator has approved Amen’s biosimilar, Bkemv,  to treat rare blood disorders, according to a statement from the Food and Drug.

Read More